NYSE · EHAB
Enhabit, Inc.
$13.80+$0.01 (+0.07%)
Enhabit, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.95% below the high.
Loading market information…
NYSE · AGL · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Agilon Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 35.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Agilon Health, Inc.’s forward annual dividend is $1.80 per share, paid quarterly. The forward yield is 2.09% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Agilon Health, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$1.23. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Agilon Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:47 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | $0.73+1,082.44% vs estimate | $1.53B+1.93% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$6.50-3,511.11% vs estimate | $1.52B+0.26% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$7.25-190.0% vs estimate | $1.45B-1.34% vs estimate |
|---|
THE ANALYST VIEW
25 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $114.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.80+$0.01 (+0.07%)
Enhabit, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.95% below the high.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$29.36$0.00 (0.0%)
Charming Medical Limited Class A Ordinary Shares’s quoted price sits in the upper half of its reported 52-week range, 7.4% below the high.
$18.50$0.00 (0.0%)
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
$10.29-$0.36 (-3.38%)
DBV Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
$6.88-$0.25 (-3.51%)
Nakamoto Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.45% below the high.
